Recent Relevant Publications
​
Shim J, Lee JY, Jonus HC, Arnold A, Schnepp RW, Janssen KM, Maximov V, Goldsmith KC. YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma. Cancer Research. 2020 Nov 1;80(21):4741-4753. PMID:34572875
Shim J, Goldsmith KC. A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment. Cancers. 2021; 13(18):4650.
Hunter C. Jonus, Rebecca E. Burnham, Andrew Ho, Adeiye A. Pilgrim, Jenny Shim, Christopher B. Doering, H. Trent Spencer, Kelly C. Goldsmith. Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials. Oncoimmunology. 2022;11(1):2057012. PMID: 35371623; PubMed Central PMCID: PMC8966991
Ning L, Shim J, Tomov ML, Liu R, Mehta R, Mingee A, Hwang B, Jin L, Mantalaris A, Xu C, Mahmoudi M, Goldsmith KC*, Serpooshan V*. A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior. Advanced Science. 2022 May 29:e2200244. doi: 10.1002/advs.202200244. PMID: 35644929. *dual corresponding/senior authors.
Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nature Medicine. 2023 May;29(5):1092-1102. doi: 10.1038/s41591-023-02297-5. Epub 2023 Apr 3. PMID: 37012551.
Berko ER, Witek GM, Matkar S, Petrova ZO, Wu MA, Smith CM, Daniels A, Kalna J, Kennedy A, Gostuski I, Casey C, Krytska K, Gerelus M, Pavlick D, Ghazarian S, Park JR, Marachelian A, Maris JM, Goldsmith KC, Radhakrishnan R, Lemmon MA, Mossé YP. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. Nature Communications. 2023 May 5;14(1):2601. doi: 10.1038/s41467-023-38195-0. PMID: 37147298
Jasmine Y. Lee, Hunter C. Jonus, Arhanti Sadanand, Gianna M. Branella, Victor Maximov, Suttipong Suttapitugsakul, Matthew J. Schniederjan, Jenny Shim, Kiran K. Parwani, Andrew Fedanov, Adeiye Pilgrim, Jordan Silva, Christopher B. Doering, Ronghu Wu, H. Trent Spencer, Kelly C. Goldsmith. Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. Cell Reports Medicine. 2023 Jun 20;4(6):101091. doi: 10.1016/j.xcrm.2023.101091.PMID: 37343516
Adeiye A. Pilgrim, Hunter C. Jonus, Andrew Ho, Anna C. Cole, Jenny Shim, Kelly C. Goldsmith. The Yes-Associated Protein (YAP) promotes resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1. OncoImmunology. 2023 Aug 5;12(1):2240678.PMID: 37554309.